XML 14 R4.htm IDEA: XBRL DOCUMENT v3.19.2
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Net revenues $ 4,337 $ 4,701 $ 8,632 $ 9,766
Cost of sales 2,443 2,668 4,883 5,418
Gross profit 1,893 2,033 3,749 4,348
Research and development expenses 276 290 537 607
Selling and marketing expenses 666 682 1,313 1,420
General and administrative expenses 296 316 589 645
Intangible assets impairment 561 521 1,030 727
Goodwill impairment   120   300
Other assets impairments, restructuring and other items 101 194 103 695
Legal settlements and loss contingencies 646 20 703 (1,258)
Other income (9) (96) (15) (299)
Operating income (loss) (644) (14) (510) 1,511
Financial expenses, net 206 236 425 507
Income (loss) before income taxes (850) (250) (934) 1,004
Income taxes (179) (76) (170) (30)
Share in losses (income) of associated companies, net   (8) 4 66
Net income (loss) (671) (166) (768) 968
Net income attributable to non-controlling interests 18 10 26 24
Net income (loss) attributable to Teva (689) (176) (794) 944
Dividends on preferred shares   65   130
Net income (loss) attributable to ordinary shareholders $ (689) $ (241) $ (794) $ 814
Earnings (loss) per share attributable to ordinary shareholders:        
Basic $ (0.63) $ (0.24) $ (0.73) $ 0.80
Diluted $ (0.63) $ (0.24) $ (0.73) $ 0.80
Weighted average number of shares (in millions):        
Basic 1,092 1,018 1,091 1,018
Diluted 1,092 1,018 1,091 1,020